L-Cycloserine
- Generic Name
- L-Cycloserine
- Brand Names
- Seromycin
- Drug Type
- Small Molecule
- Chemical Formula
- C3H6N2O2
- CAS Number
- 339-72-0
- Unique Ingredient Identifier
- AK7DRB7FMO
- Background
Antibiotic substance produced by Streptomyces garyphalus.
- Indication
本品与其他抗结核药联合，用于经一线药物（如吡嗪酰胺、链霉素、异烟肼、利福平和乙胺丁醇）治疗失败的患者。本品还可用于治疗非结核分枝杆菌感染如鸟复合分枝杆菌病的治疗。
- Associated Conditions
- Pulmonary Tuberculosis (TB), Tuberculosis, Extrapulmonary, Grade 1, grade 2, grade 3, grade 4 Urinary Tract Infection
- Associated Therapies
- -
Once Weekly D-cycloserine for Schizophrenia
- First Posted Date
- 2009-08-24
- Last Posted Date
- 2013-11-20
- Lead Sponsor
- Massachusetts General Hospital
- Registration Number
- NCT00964041
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2009-08-24
- Last Posted Date
- 2018-02-06
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 54
- Registration Number
- NCT00963924
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
The Role of the Glutamatergic System in the Extinction of Conditioned Reinforcement Processes
- First Posted Date
- 2009-06-24
- Last Posted Date
- 2011-11-28
- Lead Sponsor
- Central Institute of Mental Health, Mannheim
- Target Recruit Count
- 80
- Registration Number
- NCT00926900
- Locations
- 🇩🇪
Central Institute of Mental Health, Mannheim, Germany
Imaginal Exposure & D-Cycloserine (DCS) for Posttraumatic Stress Disorder (PTSD)
- First Posted Date
- 2009-04-03
- Last Posted Date
- 2021-08-16
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 41
- Registration Number
- NCT00875342
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
Transcranial Direct Current Stimulation (tDCS) Augmentation by D-Cycloserine as a Treatment for Depression
- Conditions
- Interventions
- First Posted Date
- 2009-03-26
- Last Posted Date
- 2010-09-10
- Lead Sponsor
- The University of New South Wales
- Target Recruit Count
- 5
- Registration Number
- NCT00869765
- Locations
- 🇦🇺
Black Dog Institute, University of New South Wales, Randwick, New South Wales, Australia
D-Cycloserine Augmentation of Therapy for Pediatric Obsessive-Compulsive Disorder
- Conditions
- Interventions
- First Posted Date
- 2009-03-18
- Last Posted Date
- 2012-10-17
- Lead Sponsor
- University of South Florida
- Target Recruit Count
- 30
- Registration Number
- NCT00864123
- Locations
- 🇺🇸
University of South Florida, St. Petersburg, Florida, United States
Virtual Reality and D-Cycloserine in Combat Related Psycological Trauma in Burn Service Members
- Conditions
- Interventions
- Locations
- 🇺🇸
US Army Institute of Surgical Research, Ft Sam Houston, Texas, United States
D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder
- Conditions
- Interventions
- First Posted Date
- 2009-02-12
- Last Posted Date
- 2019-06-18
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 68
- Registration Number
- NCT00842309
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
D-Cycloserine Enhancement of Exposure-Based CBT for Smoking Cessation (DCSSmoking)
- First Posted Date
- 2009-01-22
- Last Posted Date
- 2017-05-01
- Lead Sponsor
- Boston University Charles River Campus
- Registration Number
- NCT00827281
- Locations
- 🇺🇸
Boston University, Boston, Massachusetts, United States
Exposure, D-Cycloserine Enhancement, and Genetic Modulators in Panic Disorder
- First Posted Date
- 2008-11-14
- Last Posted Date
- 2018-03-07
- Lead Sponsor
- Boston University Charles River Campus
- Target Recruit Count
- 180
- Registration Number
- NCT00790868
- Locations
- 🇺🇸
Boston University, Boston, Massachusetts, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.